340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

• DOI: 10.1016/j.annonc.2024.08.288
• Publication Date: 2024-09-17T19:53:39Z
• Authors: B. Pistilli; L. Pierotti; M. Lacroix-Triki; C. Vicier; J-S. Frenel; V. D'Hondt; F. Dalenc; T. Bachelot; A. Ducoulombier; M-A. Benderra; D. Loirat; D. Mayeur; G.B. Nachabeh; A. Sporchia; F. Suto; S. Michiels; N. Corcos; M.F. Mosele; F. André; G. Montagnac